BARING ASSET MANAGEMENT Ltd reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 18.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,001 shares of the company’s stock after selling 2,801 shares during the quarter. BARING ASSET MANAGEMENT Ltd’s holdings in Johnson & Johnson were worth $1,560,000 at the end of the most recent quarter.
Other hedge funds have also recently modified their holdings of the company. Lenox Wealth Advisors Inc. grew its position in shares of Johnson & Johnson by 0.6% in the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after purchasing an additional 5 shares during the period. Landmark Financial Advisors LLC grew its position in shares of Johnson & Johnson by 0.4% in the second quarter. Landmark Financial Advisors LLC now owns 1,962 shares of the company’s stock valued at $259,000 after purchasing an additional 7 shares during the period. Paradigm Financial Advisors LLC grew its position in Johnson & Johnson by 0.3% during the second quarter. Paradigm Financial Advisors LLC now owns 2,649 shares of the company’s stock valued at $350,000 after acquiring an additional 9 shares during the period. Premier Asset Management LLC grew its position in Johnson & Johnson by 0.4% during the second quarter. Premier Asset Management LLC now owns 2,749 shares of the company’s stock valued at $363,000 after acquiring an additional 12 shares during the period. Finally, Lbmc Investment Advisors LLC grew its position in Johnson & Johnson by 0.4% during the second quarter. Lbmc Investment Advisors LLC now owns 3,718 shares of the company’s stock valued at $492,000 after acquiring an additional 14 shares during the period. 65.71% of the stock is owned by hedge funds and other institutional investors.
A number of equities research analysts have issued reports on JNJ shares. Jefferies Group upped their target price on Johnson & Johnson from $157.00 to $160.00 and gave the stock a “buy” rating in a research report on Monday, October 16th. UBS Group reaffirmed a “buy” rating and issued a $148.00 target price on shares of Johnson & Johnson in a research report on Saturday, September 30th. Cowen set a $147.00 price target on Johnson & Johnson and gave the stock a “buy” rating in a research note on Friday, October 6th. Citigroup boosted their price target on Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a research note on Monday, October 23rd. Finally, Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $147.14 price target on the stock in a research note on Wednesday, December 20th. Four investment analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $145.94.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.10. The firm had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the business posted $1.68 earnings per share. equities analysts expect that Johnson & Johnson will post 7.28 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.28%. The ex-dividend date is Monday, February 26th. Johnson & Johnson’s payout ratio is presently 58.33%.
COPYRIGHT VIOLATION WARNING: “BARING ASSET MANAGEMENT Ltd Cuts Position in Johnson & Johnson (JNJ)” was reported by BBNS and is the property of of BBNS. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://baseballnewssource.com/markets/johnson-johnson-jnj-stake-lowered-by-baring-asset-management-ltd/1822829.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.